Quality of life (QoL) with palbociclib (PAL) plus endocrine therapy (ET) versus (vs) capecitabine (CAP) in luminal metastatic breast cancer (MBC) patients (pts) in the PEARL study
No Thumbnail Available
Identifiers
Date
2020-05-01
Authors
Kahan, Z.
Gil-Gil, M.
Ruiz-Borrego, M.
Carrasco, E. M.
Ciruelos, E. M.
Munoz, M.
Bermejo De Las Heras, B.
Margeli Vila, M.
Anton, A.
Casas, M.
Advisors
Journal Title
Journal ISSN
Volume Title
Publisher
Elsevier
Metrics
Export
